Your session is about to expire
← Back to Search
Decentralized Care Approach for HIV/AIDS
N/A
Waitlist Available
Led By Frederick Altice, M.D., M.A.
Research Sponsored by Yale University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to month 54
Awards & highlights
Study Summary
This trial studies decentralization of HIV care in Peru to improve retention & create evidence for future efforts in Peru & other countries.
Who is the study for?
This trial is for healthcare professionals working at primary or secondary health centers involved in the study, specifically nurses and physicians who have completed ECHO training and leaders of primary health centers. They must consent to participate.Check my eligibility
What is being tested?
The study is testing a strategy called 'decentralization' to improve HIV care retention by using NIATx (a process improvement approach) along with ECHO (a tele-mentoring model). It aims to provide insights into how decentralizing HIV services can be effectively implemented in urban areas.See study design
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to month 54
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to month 54
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Percentage of diagnosed PWH in treatment in PHC within the district
Secondary outcome measures
Effectiveness assessed as the extent of RIC and VS within the district
Trial Design
3Treatment groups
Experimental Treatment
Group I: Group 3Experimental Treatment1 Intervention
Control (month 7-24 then NIATx+ECHO (month 25-48) then Maintenance (month 49-54)
Group II: Group 2Experimental Treatment1 Intervention
Control (month 7-18) then NIATx+ECHO (month 19-42) then Maintenance (month 43-54)
Group III: Group 1Experimental Treatment1 Intervention
Control (month 7-12) then NIATx+ECHO (month 13-36) then Maintenance (month 37-54)
Find a Location
Who is running the clinical trial?
Yale UniversityLead Sponsor
1,847 Previous Clinical Trials
2,735,078 Total Patients Enrolled
National Institute of Allergy and Infectious Diseases (NIAID)NIH
3,268 Previous Clinical Trials
5,479,682 Total Patients Enrolled
Frederick Altice, M.D., M.A.Principal InvestigatorYale University
2 Previous Clinical Trials
305 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:Research Study Groups:
This trial has the following groups:- Group 1: Group 3
- Group 2: Group 1
- Group 3: Group 2
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is this clinical trial currently enrolling any new participants?
"This research endeavour, whose information was first published on the 1st of July 2023 and last amended on the 16th of June 2023, is not presently enrolling patients. Nonetheless, 233 other clinical trials are currently accommodating volunteers."
Answered by AI
Popular Categories
Share this study with friends
Copy Link
Messenger